<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Amphetamine - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/stimulants/">Stimulants</a> ‚Üí <span>Amphetamine</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>‚ö° Amphetamine</h1>
        <h2 class="chemical-name">1-Phenylpropan-2-amine</h2>
          
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Amphetamine" 
                data-category="Stimulants" 
                data-chemical="1-Phenylpropan-2-amine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Adderall</span> ‚Ä¢ <span>Dexedrine</span> ‚Ä¢ <span>Vyvanse</span> ‚Ä¢ <span>Evekeo</span> ‚Ä¢ <span>Benzedrine</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Speed</span> ‚Ä¢ <span>Uppers</span> ‚Ä¢ <span>Peep</span> ‚Ä¢ <span>Wake-ups</span> ‚Ä¢ <span>Go-pills</span> ‚Ä¢ <span>Beans</span>
            </div>
            <div name-category">
              <h4>Historical Names</h4>
              <span>Benzedrine</span> ‚Ä¢ <span>Racemic amphetamine</span> ‚Ä¢ <span>DL-amphetamine</span> ‚Ä¢ <span>Phenylisopropylamine</span>
            </div>
            <div class="name-category">
              <h4>Chemical Names</h4>
              <span>Œ±-Methylphenethylamine</span> ‚Ä¢ <span>1-Phenyl-2-aminopropane</span> ‚Ä¢ <span>Œ≤-Phenylisopropylamine</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category stimulant medical">Stimulant/Medical</span>
          <span class="legal-status schedule-2">Schedule II</span>
          <span class="duration medium">4-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/amphetamine.jpg" alt="Amphetamine tablets and capsules" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇâH‚ÇÅ‚ÇÉN</p>
            <p>MW: 135.21 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pharmaceutical Forms</h4>
          <ul>
            <li><strong>Immediate-release tablets:</strong> Round, scored, orange/peach (Adderall 5-30mg)</li>
            <li><strong>Extended-release capsules:</strong> Blue/orange capsules (Adderall XR 5-30mg)</li>
            <li><strong>Dextroamphetamine:</strong> Round tablets, various colors (Dexedrine 5-10mg)</li>
            <li><strong>Lisdexamfetamine:</strong> Capsules, blue/orange/white (Vyvanse 20-70mg)</li>
            <li><strong>Generic forms:</strong> Various shapes, colors, and markings by manufacturer</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Illicit Forms</h4>
          <ul>
            <li><strong>Diverted pharmaceuticals:</strong> Legitimate tablets/capsules sold illegally</li>
            <li><strong>Powder/crystals:</strong> White to off-white crystalline powder</li>
            <li><strong>Paste:</strong> Sticky, off-white to yellowish paste (European "speed paste")</li>
            <li><strong>Pressed tablets:</strong> Illegally manufactured tablets, various appearances</li>
            <li><strong>Capsules:</strong> Powder placed in gelatin caps</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Common Adulterants & Impurities</h4>
          <p><strong>Street speed:</strong> Caffeine, lactose, inositol, mannitol, phenacetin</p>
          <p><strong>Dangerous adulterants:</strong> Methamphetamine, cathinones, levamisole</p>
          <p><strong>Manufacturing impurities:</strong> Phenylacetone, benzyl methyl ketone</p>
          <p><strong>Pressed pills:</strong> May contain other stimulants or unknown substances</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">2.5-5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">5-15mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">15-30mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">30-60mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">High Risk</span>
          <span class="dose-amount">60mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="medical-dosing">
        <h4>Medical Dosing Guidelines</h4>
        <ul>
          <li><strong>ADHD (children):</strong> Start 2.5-5mg daily, increase by 2.5-5mg weekly</li>
          <li><strong>ADHD (adults):</strong> Start 5mg 1-2x daily, increase to 20-40mg daily</li>
          <li><strong>Narcolepsy:</strong> 5-20mg daily, up to 60mg in divided doses</li>
          <li><strong>Extended-release:</strong> Once daily dosing, 20-30mg typical</li>
          <li><strong>Maximum medical dose:</strong> Generally 40-60mg daily</li>
        </ul>
      </div>
      
      <div class="dosage-details">
        <h4>Route-Specific Information</h4>
        <ul>
          <li><strong>Oral:</strong> Standard route, 4-8 hour duration</li>
          <li><strong>Insufflated:</strong> Faster onset, shorter duration, nasal damage</li>
          <li><strong>IV/IM:</strong> Immediate onset, high abuse potential, injection risks</li>
          <li><strong>Smoking:</strong> Very fast onset, extremely short duration, lung damage</li>
          <li><strong>Bioavailability:</strong> ~75% oral, higher with other routes</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Medical Warning:</strong> Amphetamine should be used only under medical supervision for legitimate conditions. Recreational doses often exceed safe medical limits and carry significant health risks.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (oral administration)</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:00</span>
          <span class="effect">Onset - increased alertness, mild euphoria</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-4:00</span>
          <span class="effect">Peak - enhanced focus, energy, confidence</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Plateau - sustained effects, potential for redosing</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-24:00</span>
          <span class="effect">Comedown - fatigue, depression, sleep disruption</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Desired Effects</h4>
          <ul>
            <li>Enhanced focus and concentration</li>
            <li>Increased energy and alertness</li>
            <li>Elevated mood and confidence</li>
            <li>Reduced fatigue</li>
            <li>Improved task performance</li>
            <li>Suppressed appetite</li>
            <li>Enhanced motivation</li>
            <li>Increased sociability</li>
          </ul>
        </div>
        
        <div class="effect-category therapeutic">
          <h4>üè• Therapeutic Effects</h4>
          <ul>
            <li>Improved attention span (ADHD)</li>
            <li>Reduced hyperactivity and impulsivity</li>
            <li>Better impulse control</li>
            <li>Enhanced working memory</li>
            <li>Improved executive function</li>
            <li>Wakefulness maintenance (narcolepsy)</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Negative Effects & Side Effects</h4>
          <ul>
            <li>Insomnia and sleep disruption</li>
            <li>Loss of appetite and weight loss</li>
            <li>Increased heart rate and blood pressure</li>
            <li>Anxiety, restlessness, agitation</li>
            <li>Headaches and dizziness</li>
            <li>Dry mouth and jaw clenching</li>
            <li>Mood swings and irritability</li>
            <li>Crash and depression (comedown)</li>
            <li>Potential for abuse and dependence</li>
          </ul>
        </div>
      </div>

      <div class="dose-response">
        <h4>üìä Dose-Response Relationship</h4>
        <ul>
          <li><strong>5-15mg:</strong> Mild alertness, subtle mood improvement</li>
          <li><strong>15-30mg:</strong> Clear focus enhancement, moderate euphoria</li>
          <li><strong>30-60mg:</strong> Strong stimulation, significant euphoria, side effects increase</li>
          <li><strong>60mg+:</strong> Intense effects, high risk of adverse reactions</li>
          <li><strong>Tolerance:</strong> Develops rapidly with regular use</li>
        </ul>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Amphetamine is a potent central nervous system stimulant that increases levels of dopamine, norepinephrine, and to a lesser extent serotonin. It works by reversing the direction of monoamine transporters (DAT, NET, SERT), causing release of stored neurotransmitters while simultaneously blocking their reuptake. This dual mechanism creates sustained elevation of neurotransmitter levels in synaptic clefts.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>DAT (Dopamine transporter)</strong></span>
            <span class="affinity">High affinity (IC50: ~25 nM)</span>
            <span class="function">Reward, motivation, motor control, addiction potential</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (Norepinephrine transporter)</strong></span>
            <span class="affinity">High affinity (IC50: ~7 nM)</span>
            <span class="function">Alertness, attention, cardiovascular effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (Serotonin transporter)</strong></span>
            <span class="affinity">Moderate affinity (IC50: ~1700 nM)</span>
            <span class="function">Mood effects, appetite suppression</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>VMAT2 (Vesicular transporter)</strong></span>
            <span class="affinity">Competitive inhibitor</span>
            <span class="function">Increases cytoplasmic neurotransmitter levels</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>TAAR1 (Trace amine receptor)</strong></span>
            <span class="affinity">Direct agonist</span>
            <span class="function">Modulates dopamine neuron firing, addiction resistance</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> Hepatic metabolism via CYP2D6 ‚Üí benzoic acid, hippuric acid</p>
          <p><strong>Active metabolites:</strong> None significant (unlike methamphetamine)</p>
          <p><strong>Half-life:</strong> 8-12 hours (dose and pH dependent)</p>
          <p><strong>Bioavailability:</strong> ~75% oral administration</p>
          <p><strong>Peak plasma:</strong> 1-3 hours after oral dose</p>
          <p><strong>Urinary excretion:</strong> pH dependent - acidic urine increases elimination</p>
          <p><strong>Duration:</strong> 4-8 hours immediate release, 8-12 hours extended release</p>
        </div>

        <h4>Stereochemistry & Isomers</h4>
        <div class="stereochemistry-info">
          <p><strong>Dextroamphetamine (d-amphetamine):</strong> More potent CNS effects, primarily dopaminergic</p>
          <p><strong>Levoamphetamine (l-amphetamine):</strong> More peripheral effects, cardiovascular stimulation</p>
          <p><strong>Racemic amphetamine:</strong> 1:1 mixture (Adderall contains 3:1 d:l ratio)</p>
          <p><strong>Clinical significance:</strong> Different ratios provide different effect profiles</p>
        </div>

        <h4>Neuroadaptive Changes (Chronic Use)</h4>
        <ul>
          <li><strong>Dopamine receptor downregulation:</strong> Tolerance to rewarding effects</li>
          <li><strong>Transporter upregulation:</strong> Compensatory increase in DAT/NET</li>
          <li><strong>Sensitization:</strong> Increased behavioral response to same dose</li>
          <li><strong>Structural changes:</strong> Altered dendritic spine density in reward circuits</li>
          <li><strong>Executive function:</strong> Potential long-term improvements with therapeutic use</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Cardiovascular risks:</strong> Increased heart rate, blood pressure, arrhythmias</li>
            <li><strong>Hyperthermia:</strong> Dangerous overheating, especially with exercise</li>
            <li><strong>Seizure risk:</strong> Lowered seizure threshold, especially at high doses</li>
            <li><strong>Psychosis:</strong> Paranoia, hallucinations with chronic high-dose use</li>
            <li><strong>Addiction potential:</strong> High psychological dependence risk</li>
            <li><strong>Sudden cardiac death:</strong> Rare but documented in vulnerable individuals</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Harm Reduction</h4>
          <ul>
            <li>Use only as prescribed for legitimate medical conditions</li>
            <li>Start with lowest effective dose</li>
            <li>Monitor heart rate and blood pressure</li>
            <li>Stay hydrated and avoid overheating</li>
            <li>Don't combine with other stimulants</li>
            <li>Take regular breaks to prevent tolerance</li>
            <li>Maintain proper nutrition and sleep</li>
            <li>Avoid alcohol and other drug combinations</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Medical Contraindications</h4>
        <ul>
          <li>Advanced arteriosclerosis or heart disease</li>
          <li>Moderate to severe hypertension</li>
          <li>Hyperthyroidism</li>
          <li>Glaucoma</li>
          <li>Agitated states or history of psychosis</li>
          <li>History of drug abuse</li>
          <li>Use with MAOIs (within 14 days)</li>
          <li>Known hypersensitivity to sympathomimetic amines</li>
        </ul>
      </div>

      <div class="withdrawal-info">
        <h4>üîÑ Withdrawal & Discontinuation</h4>
        <p><strong>Symptoms:</strong> Fatigue, depression, increased appetite, sleep disturbances, vivid dreams, psychomotor agitation or retardation</p>
        <p><strong>Timeline:</strong> Begins within hours, peaks 2-4 days, can last weeks</p>
        <p><strong>Management:</strong> Gradual taper, supportive care, monitoring for depression</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous Interactions</h4>
          <ul>
            <li><strong>MAOIs:</strong> Hypertensive crisis, potentially fatal</li>
            <li><strong>Other stimulants:</strong> Additive cardiovascular toxicity</li>
            <li><strong>Tricyclic antidepressants:</strong> Enhanced cardiovascular effects</li>
            <li><strong>Cocaine:</strong> Increased cardiac stress and arrhythmia risk</li>
            <li><strong>Alcohol:</strong> Masks intoxication, increased risky behavior</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Requires Monitoring</h4>
          <ul>
            <li><strong>SSRIs:</strong> Potential serotonin syndrome (rare)</li>
            <li><strong>Blood pressure medications:</strong> Reduced effectiveness</li>
            <li><strong>Seizure medications:</strong> Lowered seizure threshold</li>
            <li><strong>Acidifying agents:</strong> Increased amphetamine elimination</li>
            <li><strong>Alkalinizing agents:</strong> Decreased amphetamine elimination</li>
          </ul>
        </div>
        
        <div class="interaction medical">
          <h4>üè• Medical Considerations</h4>
          <ul>
            <li><strong>Lithium:</strong> Risk of neurotoxicity</li>
            <li><strong>Haloperidol:</strong> Reduced amphetamine effects</li>
            <li><strong>Phenytoin:</strong> Altered seizure threshold</li>
            <li><strong>Insulin:</strong> May affect glucose metabolism</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule II</strong> - Controlled substance with accepted medical use but high abuse potential. Requires prescription with no refills allowed.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class B</strong> - Controlled drug. Up to 5 years for possession, 14 years for supply. Available by prescription.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá™üá∫ European Union</h4>
            <p><strong>Controlled substance</strong> - Varies by country. Generally requires prescription and is controlled due to abuse potential.</p>
          </div>
          <div class="jurisdiction">
            <h4>üåè International</h4>
            <p><strong>UN Convention</strong> - Listed in Schedule II of the 1971 Convention on Psychotropic Substances.</p>
          </div>
        </div>
        
        <div class="legal-consequences">
          <h4>‚öñÔ∏è Legal Issues</h4>
          <ul>
            <li><strong>Prescription fraud:</strong> Serious felony charges</li>
            <li><strong>Distribution:</strong> Trafficking charges even for small amounts</li>
            <li><strong>Driving under influence:</strong> DUI charges possible</li>
            <li><strong>Academic/professional:</strong> Unprescribed use may violate codes of conduct</li>
            <li><strong>Sports:</strong> Banned by most athletic organizations</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1887</span>
          <p>First synthesized by Romanian chemist LazƒÉr Edeleanu</p>
        </div>
        <div class="history-event">
          <span class="year">1929</span>
          <p>Medical uses discovered, marketed as Benzedrine inhaler</p>
        </div>
        <div class="history-event">
          <span class="year">1937</span>
          <p>First used to treat "hyperkinetic" children (now ADHD)</p>
        </div>
        <div class="history-event">
          <span class="year">1940s</span>
          <p>Widespread military use during WWII for combat fatigue</p>
        </div>
        <div class="history-event">
          <span class="year">1960s-70s</span>
          <p>Peak of recreational "speed" abuse, counterculture use</p>
        </div>
        <div class="history-event">
          <span class="year">1971</span>
          <p>Controlled Substances Act - Schedule II classification</p>
        </div>
        <div class="history-event">
          <span class="year">1990s-present</span>
          <p>ADHD diagnosis expansion, increased legitimate medical use</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Cultural & Social Impact</h4>
        <p>Amphetamine has a complex dual identity as both essential medication and drug of abuse. The 1960s "speed" epidemic highlighted its dangers, while modern ADHD treatment has made it more socially acceptable. The rise of "study drugs" and cognitive enhancement has created new patterns of use among students and professionals.</p>
        
        <h4>Medical Revolution</h4>
        <p>Amphetamine's discovery of ADHD treatment effects revolutionized understanding of attention disorders and sparked decades of research into dopamine's role in executive function. It remains a first-line treatment despite ongoing debates about overdiagnosis and long-term effects.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research & Medical Uses</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>ADHD Treatment Optimization</h4>
          <p>Research focuses on optimal dosing strategies, long-term effects in children and adults, and personalized medicine approaches based on genetic factors affecting metabolism.</p>
        </div>
        
        <div class="research-item">
          <h4>Cognitive Enhancement</h4>
          <p>Studies examine amphetamine's effects on healthy individuals, ethical considerations of cognitive enhancement, and potential therapeutic uses in age-related cognitive decline.</p>
        </div>
        
        <div class="research-item">
          <h4>Addiction & Recovery</h4>
          <p>Research into amphetamine addiction mechanisms, treatment approaches, and the paradox of using stimulants to treat stimulant addiction in some cases.</p>
        </div>
        
        <div class="research-item">
          <h4>Neurodevelopmental Effects</h4>
          <p>Long-term studies on children who received amphetamine treatment, effects on brain development, and outcomes in adulthood.</p>
        </div>
      </div>

      <div class="medical-uses">
        <h4>üè• Current Medical Uses</h4>
        <ul>
          <li><strong>ADHD:</strong> First-line treatment for children and adults</li>
          <li><strong>Narcolepsy:</strong> Maintains wakefulness and reduces sleep attacks</li>
          <li><strong>Treatment-resistant depression:</strong> Adjunct therapy in specific cases</li>
          <li><strong>Obesity:</strong> Short-term appetite suppression (limited use)</li>
          <li><strong>Binge eating disorder:</strong> Lisdexamfetamine (Vyvanse) approved</li>
        </ul>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://chadd.org/">CHADD</a> - ADHD support and education</li>
          <li><a href="https://www.add.org/">ADDA</a> - Adult ADHD support</li>
          <li><a href="https://www.fda.gov/">FDA</a> - Medication guides and safety information</li>
          <li>Healthcare providers for proper diagnosis and treatment</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Addiction & Abuse</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/">SAMHSA</a> - Treatment locator and resources</li>
          <li><a href="https://www.crystalmethaddiction.org/">Stimulant Addiction Resources</a></li>
          <li><a href="https://na.org/">Narcotics Anonymous</a> - Recovery support</li>
          <li><a href="https://www.smartrecovery.org/">SMART Recovery</a> - Science-based recovery</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Academic & Research</h4>
        <ul>
          <li><a href="https://pubmed.ncbi.nlm.nih.gov/">PubMed</a> - Medical research database</li>
          <li><a href="https://www.drugabuse.gov/">NIDA</a> - Research and information</li>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - Detailed pharmacology</li>
          <li>University counseling centers for academic use concerns</li>
        </ul>
      </div>
    </div>
  </div>

  <div class="medical-balance-footer">
    <h3>‚öñÔ∏è Medicine vs. Misuse</h3>
    <p>Amphetamine represents one of medicine's most complex substances - simultaneously a life-changing treatment for millions with ADHD and narcolepsy, and a dangerous drug of abuse. When used as prescribed under medical supervision, it's generally safe and highly effective. However, recreational use, academic "enhancement," or unprescribed consumption carries significant health risks and legal consequences.</p>
    
    <p><strong>If you're struggling with attention problems, consider speaking with a healthcare provider about proper evaluation and treatment. If you're dealing with amphetamine abuse or addiction, professional help and support groups are available.</strong></p>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>